Contributions
Abstract: PB1795
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
Plerixafor, a selective inhibitor of CXCR4, can effectively mobilize the hematopoietic stem cells (HSC) depending on the dose and the study. It demonstrated also the alteration of the cellular phenotype and function of HSC compared to that with G-CSF in the animal experiments, while rare in clinical studies.
Aims
To investigate the potential influence of Plerixafor in combination with G-CSF and G-CSF alone on the mobilization efficiency, and also the phenotype and function of mobilized stem cells.
Methods
12 patients diagnosed with NHL and MM were prospectively analyzed. Patients were randomly divided into two groups (6 in G-CSF only (G) group and 6 in G-CSF plus Plerixafor (G+P) group). Patients in G group were receiving 10 μg/Kg of G-CSF for 5 days consecutively while in combine with a single dose of 240 μg/kg Plerixafor at day 5 in the G+P group. The end point of apheresis was to collect at least 2x106 CD34+ cells/kg. The cellular phenotype of mobilized peripheral blood stem cells (PBSCs) and harvest stem cells was analyzed by Flow cytometry. The gene expression profiling of CD34+ cells were analyzed by Illumina High-throughput sequencing.
Results
Plerixafor reduced the number of apheresis sessions. The mean numbers leukapheresis per person was 1.50 in G+P group and 2.17 in the G group. The median CD34+ cell counts in peripheral blood increased 7.88 times after the administration of Plerixafor in G+P group as compared prior-Plerixafor，While 1.69 times increase in G group at the time of apheresis. Compared with G-CSF alone, there was a trend towards higher level of monocytes (p = 0.031) and lymphocytes (p = 0.095) and lower level of granulocytes (p = 0.076) in the mobilized PBSCs in G+P group, particularly a significantly higher percentage of B cells (p = 0.045) and Treg cells (p = 0.079) . The gene expression profiling involved in cell proliferation (p<0.0001) and hematopoiesis(p<0.0001) were significantly increased in G+P group, which associated with better engraftment.
Conclusion
A single dose of Plerixafor in combination with G-CSF increase the mobilization efficiency and facilitate the cellular phenotyping and function of hematopoietic stem cells compared to that with G-CSF alone, which may promote a superior and long-term engraftment.
Keyword(s): AMD3100, G-CSF, HSCT
Abstract: PB1795
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
Plerixafor, a selective inhibitor of CXCR4, can effectively mobilize the hematopoietic stem cells (HSC) depending on the dose and the study. It demonstrated also the alteration of the cellular phenotype and function of HSC compared to that with G-CSF in the animal experiments, while rare in clinical studies.
Aims
To investigate the potential influence of Plerixafor in combination with G-CSF and G-CSF alone on the mobilization efficiency, and also the phenotype and function of mobilized stem cells.
Methods
12 patients diagnosed with NHL and MM were prospectively analyzed. Patients were randomly divided into two groups (6 in G-CSF only (G) group and 6 in G-CSF plus Plerixafor (G+P) group). Patients in G group were receiving 10 μg/Kg of G-CSF for 5 days consecutively while in combine with a single dose of 240 μg/kg Plerixafor at day 5 in the G+P group. The end point of apheresis was to collect at least 2x106 CD34+ cells/kg. The cellular phenotype of mobilized peripheral blood stem cells (PBSCs) and harvest stem cells was analyzed by Flow cytometry. The gene expression profiling of CD34+ cells were analyzed by Illumina High-throughput sequencing.
Results
Plerixafor reduced the number of apheresis sessions. The mean numbers leukapheresis per person was 1.50 in G+P group and 2.17 in the G group. The median CD34+ cell counts in peripheral blood increased 7.88 times after the administration of Plerixafor in G+P group as compared prior-Plerixafor，While 1.69 times increase in G group at the time of apheresis. Compared with G-CSF alone, there was a trend towards higher level of monocytes (p = 0.031) and lymphocytes (p = 0.095) and lower level of granulocytes (p = 0.076) in the mobilized PBSCs in G+P group, particularly a significantly higher percentage of B cells (p = 0.045) and Treg cells (p = 0.079) . The gene expression profiling involved in cell proliferation (p<0.0001) and hematopoiesis(p<0.0001) were significantly increased in G+P group, which associated with better engraftment.
Conclusion
A single dose of Plerixafor in combination with G-CSF increase the mobilization efficiency and facilitate the cellular phenotyping and function of hematopoietic stem cells compared to that with G-CSF alone, which may promote a superior and long-term engraftment.
Keyword(s): AMD3100, G-CSF, HSCT